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Abstract: Heart transplantation is an accepted therapeutic modality for end-stage congenital heart disease for both biven-
tricular and univentricular anomalies. Many transplant centers have pushed the limits of transplantation to include patients 
with high pulmonary vascular resistance, high panel reactive antibodies, positive cross-matches, and ABO-
incompatibility. Excellent results have been possible, particularly with the development of improved diagnostic and thera-
peutic algorithms to prevent and treat rejection, infection, and post-transplant lymphoproliferative disease. Late graft fail-
ure and chronic rejection remain vexing problems. The vast majority of patients with biventricular congenital heart dis-
ease have undergone prior cardiac surgical procedures. Indications for transplantation in this subgroup are primarily pro-
gressive refractory heart failure following prior cardiac surgical reconstructive procedures. Contraindications to transplan-
tation mimic those for other forms of end-stage heart disease. A determination of pulmonary vascular resistance is impor-
tant in listing patients with biventricular congenital heart disease for heart transplantation. Modifications in the implant 
technique are necessary and vary depending on underlying recipient anatomy. Risk factors for perioperative outcomes in 
patients with biventricular congenital heart disease include the need for reoperation, the degree of anatomic reconstruction 
necessary during the implant procedure, and the degree of antibody sensitization, in addition to a number of other recipi-
ent and donor factors. Postoperative outcomes and survival are very good but remain inferior to those with cardiomyopa-
thy in most series. In conclusion, patients with end-stage biventricular congenital heart disease represent a complex group 
of patients for heart transplantation, and require careful evaluation and management to ensure optimal outcomes. 
Keywords: Perioperative and long-term outcomes, Biventricular, Cardiac transplantation, Congenital heart disease, Failing ven-
tricle, Heart failure, Heart transplant, Orthotopic heart transplantation, Pediatric cardiac surgery. 
INTRODUCTION 
  The first pediatric heart transplant was performed in 1967 
for an eighteen day old patient with congenital heart disease 
(CHD) consisting of Ebstein’s anomaly [1]. The allograft 
survived six hours. It was not until twenty years later, fol-
lowing the introduction of cyclosporine A, that the next pe-
diatric heart transplant was performed. In the 1980’s and 
1990’s, heart transplantation became an accepted treatment 
modality for end-stage heart disease for adults and children. 
Due to the shortage of donor organs, mechanical circulatory 
support devices have been used with increasing frequency in 
the management of end-stage heart disease, particularly in 
adults. In the past five years, the Berlin Heart ventricular 
assist device has been used with greater frequency in chil-
dren and neonates, although this device is not formally ap-
proved for widespread use in the United States. To obviate 
the donor shortage and the prolonged waiting time in pediat-
ric heart transplantation, other recent advances have included 
transplantation across a positive cross-match and ABO-
incompatible transplantation in selected patients up to two 
years of age. 
  There is an increasing body of literature concerning heart 
transplantation for CHD, both in pediatric and adult recipi-
ents. Since the majority of CHD lesions can be repaired or  
 
*Address correspondence to this author at the One Children’s Place, 
Suite 5S50, St. Louis Children’s Hospital, St. Louis, MO 63110, USA;  
Tel: 1-314-454-6165; Fax: 1-314-454-2381;  
E-mail: huddlestonc@wustl.edu 
palliated, primary heart transplantation has a very limited 
role in the management of these patients. This is in contra-
distinction to the 1980’s, when a number of centers, includ-
ing ours, performed primary heart transplantation for hy-
poplastic left heart syndrome (HLHS). Improved outcomes 
following staged palliation for single-ventricle lesions, in-
cluding HLHS, as well as inevitable waiting list mortality, 
have swung the pendulum towards palliation or repair of 
CHD rather than primary transplantation. As a result, in the 
last two decades, the majority of CHD patients undergoing 
heart transplantation have failed prior cardiac surgical proce-
dures.  
  There is little data regarding heart transplantation for 
CHD patients with only biventricular physiology. Published 
studies have grouped all patients with CHD into one entity, 
and compared the outcomes of CHD patients to other patient 
populations, most notably cardiomyopathy. The largest sin-
gle subset of patients with CHD who undergo heart trans-
plantation have failed surgical palliation for single-ventricle 
lesions. End-stage CHD of the biventricular form is a het-
erogeneous group of patients, almost all of whom have un-
dergone prior surgical repair. This monograph will highlight 
the indications, contraindications, recipient anatomic consid-
erations, donor evaluation, surgical techniques, survival, and 
long-term outcomes following heart transplantation for 
biventricular CHD, both in adult and pediatric recipients. 
Since there are no randomized clinical trials, the recommen-
dations are based on single-center or registry reviews as well 
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with biventricular versus univentricular CHD have not been 
routinely compared in most studies, overall conclusions 
about survival and outcomes for patients with only biven-
tricular CHD are difficult to determine, particularly consider-
ing the wide heterogeneity in recipient diagnoses, prior op-
erations, age, and clinical status. 
INDICATIONS 
  The indications for heart transplantation are covered 
elsewhere in this issue. There are three broad subsets of pa-
tients: those with CHD, those with cardiomyopathy, and 
those undergoing retransplantation. Since 1990, the percent-
age of patients with CHD has been decreasing while the per-
centage of patients in the other two categories has been in-
creasing. This is primarily due to the avoidance of heart 
transplantation as primary therapy for patients with HLHS. 
In the current era, CHD is present in two thirds of pediatric 
recipients, compared to 80% in earlier eras when transplanta-
tion was used as primary therapy for HLHS [2]. Data from 
the 2010 International Society for Heart and Lung Trans-
plantation Registry indicate that CHD is present in 63% of 
patients < 1 year of age, 37% of patients 1-10 years of age, 
25% in patients 11-17 years of age, and 2% of adult recipi-
ents [3]. The diagnosis of CHD became less prevalent across 
all age groups over the past decade. This was most pro-
nounced in infants. On the other hand, cardiomyopathy and 
retransplantation have been increasing in frequency as indi-
cations for heart transplantation. 
  In biventricular CHD, there are three main indications for 
heart transplantation: 
•  Refractory heart failure: this represents the most 
common indication for heart transplantation. While the 
long-term results of surgical repair for CHD are quite 
good, survival is inferior to that of the general popula-
tion. A number of patients will have poor systemic ven-
tricular function, often late following palliation or cor-
rection of CHD. This may be due to myocardial injury 
sustained during repair, poor myocardial preservation 
during surgery, or idiopathic progressive ventricular 
dysfunction, all of which are amenable to heart trans-
plantation. While any patient with CHD can experience 
heart failure, the more common diagnoses are listed be-
low: 
o  Transposition of the great arteries (TGA): Pa-
tients with D-TGA who underwent the Mustard or 
Senning atrial switch procedures in the 1970’s and 
1980’s can experience progressive heart failure 
since the systemic ventricle is a right ventricle. This 
can result in progressive ventricular dysfunction, re-
sulting in severe systemic atrioventricular valve in-
sufficiency. Survival is inferior to age-matched con-
trols [4]. Another group of patients are those with 
L-TGA who underwent classical surgical repair 
whereby the systemic ventricle remains a right ven-
tricle. Although sudden cardiac death may occur, 
most deaths are due to progressive systemic right 
ventricular failure, which is treatable with cardiac 
transplantation.  
o  Tetralogy of Fallot: Patients entering the third dec-
ade of life following repair of tetralogy of Fallot 
have decreased survival compared to age-matched 
controls [5]. In some, mortality is from sudden car-
diac death thought to be due to ventricular tachyar-
rhythmias. In others, there is progressive heart fail-
ure, which would be amenable to heart transplanta-
tion.  
•  Unreconstructable CHD: with advancements in car-
diac surgical techniques, this entity has become increas-
ingly rare. With the plateau of pediatric heart donors in 
the United States at 360 annually, there is significant 
waiting list mortality, particularly for the youngest pa-
tients. As a result, every attempt is made to repair or pal-
liate CHD, in order to prolong the use of the native heart 
as long as possible. A number of rare lesions not ame-
nable to surgical intervention are listed below, most of 
which fall in the category of univentricular CHD: 
o  Coronary circulation anomalies: Patients with 
pulmonary atresia with intact ventricular septum 
(PAIVS) along with right-ventricle dependent coro-
nary circulation are at high risk for sudden death 
due to tenuous coronary perfusion [6]. This is usu-
ally in the spectrum of univentricular CHD. Like-
wise, patients with HLHS of the mitral stenosis and 
aortic atresia variety can have coronary sinusoids 
from the small hypertensive left ventricle. In a sub-
set of these patients, the native coronary arteries 
may contain stenoses, which would make surgical 
palliation less attractive. Cardiac catheterization 
should be performed in these two patient groups: 
those with native coronary artery stenoses should 
undergo consideration for primary heart transplanta-
tion as the mortality of surgical palliation is high. 
o  Neonatal Ebstein’s anomaly: Patients with severe 
neonatal Ebstein’s anomaly have marked cardio-
megaly from severe tricuspid insufficiency, signifi-
cant right atrial dilation, poor right ventricular func-
tion, and functional pulmonary atresia, with poor 
antegrade flow into the pulmonary arteries. Surgical 
repair carries high risk in symptomatic neonates 
with severe Ebstein’s anomaly [7]. Primary heart 
transplantation should be considered on a case-by-
case basis. 
o  Severe multi-valve disease: Most atrioventricular 
or semilunar valve insufficiency or stenosis can be 
addressed surgically without transplantation. In a 
subset of patients, the risks of valve repair or re-
placement are high, especially if multiple valves are 
involved, usually in the setting of single-ventricle 
physiology. Rarely, this may occur in patients with 
biventricular CHD. Primary heart transplantation 
should be considered on an individualized basis. 
o  Complex heterotaxy syndromes: The vast major-
ity of heterotaxy patients undergo surgical interven-
tion: most undergo staged palliation to achieve a 
single-ventricle circulation, while a minority un-
dergo biventricular repair. A small subset of pa-
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atrioventricular or semilunar valvar abnormalities 
along with associated total anomalous pulmonary 
venous return, may be considered for primary heart 
transplantation in select circumstances [8].  
•  Refractory life-threatening arrhythmias: this is seen 
in a minority of patients, most of whom have structur-
ally normal hearts without CHD. These ventricular ar-
rhythmias can not be controlled by automatic implant-
able cardioverter defibrillator devices, medications, or 
ablation techniques. Transplantation may be offered as 
an option of last resort. 
  A recent analysis of 307 pediatric heart transplant pa-
tients from our institution transplanted over a 24 year period 
[9] revealed that CHD was present in 57% of patients, while 
cardiomyopathy was present in 39% and retransplantation in 
4%. Among those with CHD, biventricular anomalies were 
present in 20% (35 of 174 patients). In our series, TGA was 
the most common diagnosis in patients with biventricular 
CHD, accounting for 31% of patients (11 of 35 patients). 
Aortic stenosis was present in 5 patients, atrioventricular 
canal defects in 4 patients, tetralogy of Fallot in 3 patients, 
and ventricular septal defects in 3 patients. Other anomalies 
were present in an additional 9 patients. 
  The largest cohort of patients with biventricular CHD 
undergoing heart transplantation comes from Lamour and 
coworkers [10] who merged the Pediatric Heart Transplant 
Study database (pediatric patients, 1993-2002, n=367) and 
the Cardiac Transplant Registry Database (adult patients, 
1990-2002, n=121). They identified 488 adult and pediatric 
patients with univentricular and biventricular CHD who un-
derwent cardiac transplantation at six months of life or later. 
A total of 366 patients younger than 6 months of age were 
excluded since 80% of them underwent primary heart trans-
plantation for CHD; the rest underwent transplantation less 
than six months after their last surgery. Those two subsets 
were thought to represent patients whose results would not 
be generalizable to the older CHD patients. Most of the ex-
cluded patients had univentricular CHD, although some had 
biventricular CHD. There were 176 patients (36%) with 
univentricular lesions among the remaining 488 patients. 
This left 312 patients with biventricular CHD (64%). whose 
various underlying lesions are shown in Table 1. While this 
study did not specifically stratify patients based on biven-
tricular versus univentricular CHD, a number of comments 
can be made: Of the patients with biventricular CHD, TGA, 
either D- or L-TGA, accounted for the biggest subset of 
biventricular CHD patients (97 patients, 31%). This was due 
to systemic ventricular failure, often a systemic right ventri-
cle. The second largest subgroup represented those with ei-
ther right or left ventricular outflow tract anomalies (87 pa-
tients, 28%). Most right ventricular outflow tract lesions had 
tetralogy of Fallot. Patients with septal defects (atrial, ven-
tricular, and atrioventricular septal defects) represented the 
third largest cohort (75 patients, 24%).  
  The group at Columbia University analyzed 106 patients 
with complex congenital heart disease, both univentricular 
and biventricular, who underwent heart transplantation [11]. 
Unlike the earlier study [10], patients younger than six 
months of age were not excluded. As a result, single ventri- 
 
Table 1.  The Distribution of Various Diagnoses Among Pediat-
ric and Adult Patients with Biventricular CHD > 6 
Months of Age who Underwent Heart Transplantation 
Between 1990-2002. Adapted from (Lamour 2009). 
 Number  Percentage 
D-Transposition of the great arteries  58  19% 
Right ventricular outflow tract lesions  49  16% 
Ventricular and/or atrial septal defects  38  12% 
Left ventricular outflow tract lesions  38  12% 
L-Transposition of the great arteries  39  13% 
Complete atrioventricular canal defect  37  12% 
Other biventricular CHD lesions  53  17% 
TOTAL 312  100% 
 
cle lesions predominated, and accounted for 58.5% of all 
patients. Biventricular CHD was present in 44 patients, with 
transposition representing the biggest cohort (D-TGA in 10, 
L-TGA in 6), followed by right ventricular outflow tract le-
sions (tetralogy of Fallot in 9 and PAIVS in 8), Ebstein’s 
anomaly in 3, and other diagnoses in 13. Some of the PAIVS 
patients were single ventricle patients. The study did not 
differentiate between univentricular and biventricular CHD 
with respect to outcomes analysis.  
  As a result of the above studies, patients with biventricu-
lar CHD undergoing heart transplantation belong to the fol-
lowing three patient substrates: 
•  Progressive systemic right ventricular failure: This 
occurs in the setting of unrepaired or physiologically-
repaired congenitally-corrected TGA or following atrial 
switch procedures for D-TGA [12]. It represents the 
most common indication for heart transplantation in 
older patients with biventricular CHD [2]. 
•  Progressive systemic left ventricular failure: A number 
of these patients may have septal defects (ventricular, 
atrial, and atrioventricular septal defects). Patients with 
coronary complications following the arterial switch 
procedure for D-TGA also fall in this category.  
•  Progressive right ventricular failure: This occurs pri-
marily in patients with tetralogy of Fallot or double out-
let right ventricle following surgical repair, where the 
systemic ventricle is a left ventricle. Severe Ebstein’s 
anomaly also falls into this category. 
CONTRAINDICATIONS 
  There are a number of contraindications to heart trans-
plantation, which are covered elsewhere in this issue. The 
following list represents contraindications to transplantation, 
which applies to patients with biventricular CHD as well as 
any other patients undergoing consideration for heart trans-
plantation: 
•  Multiorgan dysfunction or failure: severe hepatic or 
renal dysfunction is a relative contraindication since low 
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kidney disease. Patients with either liver or kidney dis-
ease are at increased risk for early mortality following 
heart transplantation [3]. Often, renal dysfunction im-
proves following heart transplantation. This needs to be 
balanced against the fact that calcineurin inhibitors nec-
essary for immunosuppression are associated with renal 
insufficiency. Combined pediatric heart-kidney and 
heart-liver transplant procedures have been reported but 
are reserved for very select circumstances. 
•  Elevated irreversible pulmonary vascular resistance 
(PVR): A determination of PVR is essential for listing 
for heart transplantation, and is especially applicable to 
patients with biventricular CHD. In the past, a PVR > 4 
Wood units*m
2 without response to pulmonary vasodi-
lators was considered a contraindication for heart trans-
plantation [13]. With advances in postoperative care, 
and with development of treatment algorithms for pa-
tients with pulmonary hypertension, these guidelines 
have been relaxed. In the most recent decade, it is now 
acceptable to transplant patients with a PVR below 6 
Wood units*m
2 and a transpulmonary gradient below 15 
mm Hg [14]. Patients with a PVR between 6-7 Wood 
units*m
2 may still be considered for transplantation al-
beit at increased risk. Other centers have used a cutoff of 
5 Wood units*m2 and a transpulmonary gradient below 
12 mm Hg [15]. If PVR is >7 Wood units*m
2, then 
physiologic testing with pulmonary vasodilators, such as 
inhaled nitric oxide, 100% oxygen, prostaglandins, or 
adenosine, should be performed. If the PVR drops below 
7 Wood units*m
2, then transplantation may be offered, 
although the perioperative mortality and morbidity will 
be increased due to pulmonary hypertension. Careful 
donor selection is important to achieve an acceptable 
outcome in these high-risk patients. Some have advo-
cated the use of oversized male donors in order to im-
prove perioperative outcomes. Pulmonary vasodilators, 
including inhaled nitric oxide and milrinone, should be 
used liberally in the postoperative period. If the PVR 
does not fall with physiologic testing during the pre-
transplant evaluation, then patients should be placed on 
chronic pulmonary vasodilators such as intravenous 
prostacyclin, oral sildenafil or bosentan, in combination 
with inotropic support in order to decrease the left ven-
tricular end diastolic pressure. Repeat determination of 
the PVR should be performed every 3-6 months. In 
some patients, pulmonary vascular remodeling may ren-
der them candidates for heart transplantation. In others, 
implantation of a ventricular assist device can result in a 
decrease in the PVR, thought to be due to unloading of 
the left ventricle, resulting in a decrease in the left atrial 
pressure [16-18]. Another option is combined heart-lung 
transplantation, although the long-term outcomes with 
heart-lung transplantation are significantly worse com-
pared with isolated heart transplantation. An alternative 
is heterotopic heart transplantation, where the trans-
planted heart acts as a biological ventricular assist de-
vice.  
•  Incurable malignancy: Active malignancy in the re-
cipient is a contraindication for heart transplantation. 
The dilemma arises when there has been remission for a 
period of time. Listing for heart transplantation in this 
setting should be individualized, taking into account the 
expected cancer-free survival of the patient. 
•  Uncontrolled infection: Heart transplantation should be 
deferred until the infection has been controlled. An ex-
ception is driveline infections in the setting of ventricu-
lar assist devices, which can be controlled but not elimi-
nated. Heart transplantation will treat the underlying 
cardiac dysfunction as well as the infection by removal 
of the offending hardware. 
•  Human immunodeficiency virus: Most centers still 
consider this an absolute contraindication for heart 
transplantation, although advances in retroviral therapy 
have led some to offer heart transplantation in this set-
ting [19].  
•  Significant psychosocial problems: The success of 
organ transplantation depends on the presence of a sup-
portive family to keep regular follow-up appointments 
and to comply with various treatment protocols. Medica-
tion non-compliance is a significant problem especially 
in the teenage transplant recipient who is doing well. 
This represents a leading cause of late graft failure. De-
velopmental delay is commonly seen in patients with 
CHD considered for heart transplantation [14]; this 
alone should not be a contraindication for heart 
transplan-tation. We and others have transplanted select 
patients with Down syndrome. Consideration for trans-
plantation should be individualized, taking into consid-
eration the overall resources available to the patient and 
the family. 
  It should be emphasized that there are very few recipient 
anatomic factors that contraindicate heart transplantation. 
Significant recipient pulmonary artery hypoplasia or pulmo-
nary vein stenosis result in increased perioperative mortality 
and morbidity; transplantation in those settings should be 
individualized. Various recipient anatomic considerations are 
discussed separately below.  
DONOR EVALUATION 
  Our donor evaluation and harvesting technique has been 
standardized, and is described in detail elsewhere [20]. We 
avoid donors who are on high doses of multiple inotropes or 
vasoactive agents, unless absolutely necessary. The size dis-
crepancy between donors and recipients varies with recipient 
age: for neonates, we consider donors who are as much as 
three times the weight of the recipient, whereas for older 
children, we prefer donors who are within 20% of the recipi-
ent weight. If the weight discrepancy is significant, delayed 
sternal closure should be performed following diuresis and 
resolution of allograft myocardial edema. In addition, the 
leftward aspect of the pericardium often needs to be resected 
and the left pleural space opened in order to allow the car-
diac apex to rest comfortably in the recipient’s mediastinal 
space. 
  It is important to obtain as much donor tissue as is feasi-
ble, in order to aid in the surgical reconstruction at the time 
of implantation. Using recipient anatomy as a guide, this 
advance planning simplifies the implant procedure. We pre-
fer to harvest the entire length of the superior vena cava, the 
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proximal portion of the descending thoracic aorta. If the 
lungs are not harvested, then we prefer to harvest the branch 
pulmonary arteries from hilum to hilum. In addition, donor 
pericardium should be harvested, as it can serve as additional 
tissue for reconstruction. We do not trim the donor organ 
until the time of implantation. 
SURGICAL TECHNIQUE 
  The technical challenges in performing the cardiac trans-
plant procedure have been overcome, even for the most 
anomalous recipient anatomic lesions. In the setting of expe-
rienced surgical transplant centers, outcomes of heart trans-
plantation for CHD approach but remain inferior to those for 
cardiomyopathy, due to recipient factors and the increased 
complexity of the surgical implant procedure. 
  Care should be taken during redo sternotomy to avoid 
catastrophic mediastinal hemorrhage. It is important to care-
fully plan for the operation, including review of prior opera-
tive reports and imaging studies. We routinely obtain preop-
erative chest CT scans with intravenous contrast in order to 
identify retrosternal structures and locations of major ves-
sels. The groin vessels often need to be exposed. Following 
recipient cardiectomy, it is important to achieve surgical 
hemostasis prior to allograft implantation. 
  Residual recipient anatomic lesions that are not addressed 
by recipient cardiectomy should be addressed and repaired. 
Failure to address residual lesions is one reason for the 
higher mortality seen in earlier eras for patients transplanted 
for CHD [21]. In most univentricular lesions, this will re-
quire reconstruction of the pulmonary arteries, typically with 
patch material. This is not often needed in patients with 
biventricular CHD.  
  Most cyanotic CHD patients who have undergone prior 
surgery will have aortopulmonary collaterals, which can re-
sult in a large amount of pulmonary venous return entering 
the left atrium. In addition to obscuring the surgical field, 
this increased return also rewarms the allograft during im-
plantation. This can be addressed by using a left ventricular 
vent, decreasing the flow rate on cardiopulmonary bypass 
(CPB), and cooling to a lower temperature.  
There are three options for implantation of the allograft in 
the recipient:  
•  Bicaval technique: This is the most common method 
used for implantation, as studies have shown a lower as-
sociated risk of tricuspid insufficiency, improved right 
atrial transport function and less atrial arrhythmias. 
Some patients may develop stenosis at the superior vena 
cava (SVC) anastomosis, which is amenable to balloon 
dilation and stent implantation. This technique also al-
lows for greater flexibility in anatomic reconstruction of 
the underlying CHD anomaly. 
•  Biatrial technique: In recipients smaller than 1 year of 
age, the SVC may be small and fragile, and the risk of a 
postoperative anastomotic stricture may be high. In that 
setting, a biatrial technique is advocated, whereby the 
donor right atrium is anastomosed to the recipient right 
atrium, instead of performing individual caval anasto-
moses.  
•  Individual pulmonary vein technique: There is little 
data to support performing isolated right and left pulmo-
nary venous anastomoses, although this has been advo-
cated by some in adult heart transplantation, in order to 
decrease the incidence of left atrial thrombus formation 
and resultant thromboembolism [22]. In the pediatric 
population, individual pulmonary venous anastomoses 
are more difficult, especially in recipients with dilated 
left atria where there is wide separation of the recipient 
pulmonary venous ostia. The technique may also result 
in a higher incidence of atrial arrhythmias and pulmo-
nary vein stenosis. 
  Various anatomic subtypes of biventricular CHD require 
variations in the implant technique. These are discussed be-
low. 
Bilateral superior vena cavae 
  A left SVC, when present, most commonly drains into 
the right atrium through a dilated coronary sinus. We prefer 
to alter the recipient cardiectomy so as to keep the coronary 
sinus and inferior vena cava together en bloc, which is su-
tured to the donor inferior vena cava (Fig. 1A). Alterna-
tively, the left SVC may be anastomosed to the donor in-
nominate vein, although this can result in stenosis or bleed-
ing due to the fragile nature of the innominate vein, espe-
cially in smaller patients (Fig. 1B).  
  In rare instances, a left SVC may drain directly into the 
roof of the left atrium, known as a Raghib association. In this 
situation, the left SVC is repaired either by an anastomosis to 
the left innominate vein (Fig. 1B) or by construction of an 
intraatrial baffle from the roof of the left atrium to the right 
atrium (Fig. 1C). The latter technique increases CPB time 
and myocardial ischemia time, and may negatively impact 
early perioperative outcomes. 
Congenitally-Corrected Transposition of the Great Ar-
teries 
  Patients with CCTGA represent a large percentage of 
patients with biventricular CHD undergoing heart transplan-
tation. In the most common form of this lesion, {S,L,L} 
CCTGA, the right atrium is right-sided and receives sys-
temic venous return. The blood drains via the mitral valve 
into the anatomic left ventricle, which is right-sided and rep-
resents the pulmonary ventricle. The left atrium is left-sided 
and receives pulmonary venous return. The blood drains via 
the tricuspid valve into the anatomic right ventricle, which is 
left-sided and represents the systemic ventricle. The aorta is 
usually to the left and slightly anterior to the main pulmo-
nary artery. Associated abnormalities include the presence of 
a ventricular septal defect, pulmonary stenosis, and Ebstei-
noid malformation of the tricuspid valve. A less common 
form is CCTGA with situs inversus, known as {I,D,D} 
CCTGA. 
  In older eras, cardiac surgical palliation was in the form 
of simpler procedures that maintained the morphological 
right ventricle as the systemic ventricle. With time, this sys-
temic right ventricle failed, resulting in systemic right ven-
tricular dilatation and systemic tricuspid regurgitation. Over 
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formed more liberally, which is a combination of an atrial 
and an arterial switch procedure. This results in a systemic 
left ventricle, and is expected to improve long-term out-
comes. 
  At the time of transplantation, the recipient’s ascending 
aorta is transected quite superiorly, where the aorta is closer 
to the midline. The main pulmonary artery is transected at 
the pulmonary artery bifurcation, and the incision is ex-
tended into the proximal origin of the left pulmonary artery. 
The rightward aspect of the pulmonary arteriotomy is closed, 
which moves the pulmonary artery bifurcation leftward. This 
avoids kinking of the pulmonary arteries by the midline as-
cending aorta. 
  During implantation, the pulmonary artery anastomosis is 
done before the aortic anastomosis, in order to allow a clear 
and unobstructed view of the surgical field. The donor as-
cending aorta is kept long and anastomosed to the distal as 
pect of the recipient ascending aorta. This moves the position 
of the ascending aorta rightward, corresponding to the left-
ward move in the main pulmonary artery anastomosis done 
earlier (Fig. 2). 
Situs inversus 
  Situs inversus occurs at a rate of 2/10,000 population. 
Patients may have severe CHD associated with single ventri-
cle physiology, or may have isolated cardiomyopathy as in 
biventricular CHD. In situs inversus, the right atrium is left-
sided, along with the SVC and inferior vena cava. The left 
atrium and pulmonary veins are right-sided. Dextrocardia is 
often present, with the cardiac apex pointing to the right. The 
aorta is to the left of the main pulmonary artery (Fig. 3A). 
  The main surgical challenge lies in routing of the sys-
temic venous return in the transplanted heart. During car-
diectomy, the atrial septum should not be resected, as it will 
be used to reroute pulmonary venous drainage. The aorta and 
main pulmonary artery are transected distally. The recipient 
atrial septum is mobilized by dividing it superiorly and infe-
riorly for extra mobility. This is then anastomosed to the left 
atrial free wall, anterior to the right pulmonary veins. A 
separate atriotomy is made anterior to the left pulmonary 
veins, which will serve as the recipient neo-left atrium, 
which is now left-sided, corresponding to the donor heart. 
The leftward aspect of the right atrial cuff is closed, which 
moves the right atrial cuff rightward. The right atrial anas-
tomosis is performed after the left atrial anastomosis. The 
pulmonary artery anastomosis is performed next, using a 
similar technique as described above for CCTGA, whereby 
an incision is made in the left pulmonary artery, which 
moves the pulmonary artery anastomosis leftward (Fig. 3). 
Heterotaxy 
  Heterotaxy syndromes (also known as right or left atrial 
isomerism) often accompany situs inversus lesions. There 
are abnormalities of systemic and pulmonary venous return. 
The majority of heterotaxy patients fall in the univentricular 
CHD category. The recipient operation combines elements 
of CCTGA and situs inversus. Our technique has been pre-






































































  Often, dextrocardia is associated with situs inversus, 
which was addressed previously. If dextrocardia is present 
with a normal situs solitus, then heart transplantation is chal-
lenging, as this may lead to a rightward rotation of the car-
diac apex, which may distort the tricuspid valve and the in-
terventricular septum. If the pericardial space is dilated, this 
is not a major concern. If the pericardial space is not en-
larged, then the left pericardium should be excised in order 
to allow the cardiac allograft to be positioned normally in the 
left chest. 
SURVIVAL 
  Overall survival following heart transplantation for all 
types of CHD (univentricular and biventricular) is lower 
compared to patients with cardiomyopathy, based on large 
registry studies. This is true for both pediatric and adult heart 
transplant recipients, and is primarily related to increased 
perioperative mortality. After excluding the perioperative 
period, survival for patients with CHD is similar to other 
diagnoses [14]. 
  Based on the most recent analysis of the International 
Society for Heart and Lung Transplantation Registry, CHD 
is a risk factor for one-year survival [3]. The highest risk 
factor for mortality at 1 year following transplantation is the 
presence of CHD in a neonate on ECMO, with a relative risk 
of 2.86. Non-neonates with CHD still accounted for a rela-
tive risk for 1-year mortality of 2.0. This increased risk for 
mortality in CHD recipients persisted in adolescents 11-17 
years of age, with a relative risk for 1-year mortality of 1.86 
[3]. Our center’s results mimic those from the ISHLT Regis-
try [9]. Our overall survival following heart transplantation 
is 84%, 77%, and 72% at 1, 5, and 10 years, respectively. 
Patients with CHD had somewhat lower survival at 80%, 
73%, and 66% at 1, 5, and 10 years, respectively. Single ven-
tricle patients following palliation had the worst outcomes, at 
70%, 58% and 50% at 1, 5, and 10 years, respectively. It 
should be noted, however, that a number of single-center 
studies from earlier eras have reported similar survival for 
patients with CHD and cardiomyopathy, although with 
smaller sample sizes and limited power [24-26]. This is 
likely not applicable to the current era due to increased pa-
tient complexity for those with CHD: borderline patients are 
being transplanted who previously would not have been con-
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undergoing primary transplantation in earlier eras has virtu-
ally disappeared. 
  Decreased survival for patients with CHD undergoing 
heart transplantation is likely due to several reasons: 
•  Reoperation: most cardiomyopathy patients have not 
had previous surgery, while most CHD patients have 
had prior surgical procedures. This increases the risk of 
bleeding and the technical complexity of the operation. 
Of the 488 patients with univentricular and biventricular 
CHD patients older than six months of age that were 
analyzed by Lamour and coworkers, 93% had under-
gone previous cardiac surgical procedures [10]. It is dif-
ficult to discern what percentage of the biventricular 
CHD patients had prior surgery, but presumably the re-
sult would be quite similar to the overall cohort. The 
number of previous sternotomies increased the ischemic 
time due to the greater need for dissection on cardio-
pulmonary bypass: those with 1-2 pervious sternotomies 
had an average ischemic time of 228 minutes, while 
those with >3 previous sternotomies had an average 
ischemic time of 242 minutes. The predicted probability 
of death increased in older recipients with older donors 
and longer ischemic times. Longer ischemic time was a 
risk factor for survival (p=0.02). 
•  Reconstruction: most patients with CHD will need to 
undergo reconstruction of the pulmonary arteries or 
aorta, or need reconstructive procedures on their sys-
temic or pulmonary venous drainage pathways. This is 
especially true for heterotaxy or situs inversus patients, 
some of whom may have biventricular CHD, although 
most will have single-ventricle anatomy. As a result, the 
reconstructive procedures that need to be performed 
along with the heart transplant procedure add to the 
technical complexity of the procedure, prolong cardio-
pulmonary bypass time, and increase short-term morbid-
ity and mortality. 
•  Antibody sensitization: Previous surgical procedures 
with exposure to blood products, along with prior use of 
homograft tissue, increase the amount of preformed an-
tibodies measured by the panel reactive antibody (PRA) 
test. A PRA > 10% typically limits the donor pool to the 
local transplant region, increasing waiting list mortality. 
Alternatively, patients may be transplanted across a 
positive cross-match, which often increases post-
transplant mortality and morbidity due to increased epi-
sodes of rejection (cellular or humoral) and the need for 
augmented immunosuppression. 
•  Elevated pulmonary vascular resistance: Some CHD 
patients have an elevated PVR, which often requires 
prolonged postoperative sedation and neuromuscular 
blockade. This increased postoperative pulmonary vas-
cular lability contributes to worse perioperative out-
comes. 
  Other factors contributing to operative mortality in pa-
tients with CHD include the clinical status of the recipient at 
the time of transplantation, the mismatch between donor and 
recipient sizes, the presence of aortopulmonary collateral 
vessels, the degree of pulmonary and systemic venous return 
anomalies, and the malalignment of the great vessels in pa-
tients with CHD [14, 27]. 
  Graft failure is the most common cause of early mortality 
following heart transplantation, especially in neonates. Sup-
portive strategies include maximal medical management, 
especially aimed at treating right ventricular dysfunction, 
including nitric oxide and prostacyclin, neuromuscular 
blockade, and ventilation with 100% FiO2.  
  Mechanical circulatory support, if needed, is extracorpo-
real membrane oxygenation (ECMO) in neonates and young 
infants. Older children may benefit from temporary centrifu-
gal circuits such as the CentriMag ventricular assist device. 
The course of mechanical circulatory support is usually one 
week or less, in order to allow improvement and recovery of 
cardiac allograft function.  
  A number of risk factors associated with early phase 
mortality and constant phase mortality have been identified 
in CHD patients with biventricular and univentricular lesions 
[10]. Those are listed in Table 2. While risk factors for CHD 
patients with only biventricular anomalies were not specifi-
cally studied, a number of inferences may be made. First, 
longer ischemic times are commonly present in patients with 
biventricular CHD, due to the need to perform redo ster-
notomy along with further dissection on cardiopulmonary 
bypass prior to recipient cardiectomy. This would result in 
increased mortality, as survival was generally worse with 
prolonged ischemic times, p=0.02. Second, older recipient 
age is also commonly present in patients with biventricular  
 
Table  2. Risk Factors Associated with Early Phase and Con-
stant Phase Mortality in All Pediatric and Adult Pa-
tients with Univentricular and Biventricular CHD > 6 
Months of Age who Underwent Heart Transplantation 
Between 1990-2002. From (Lamour 2009). 
Variable 
Relative 
Risk  p Value 
Early phase    
Previous Fontan operation  8.6  0.003 
Higher pre-transplant mean RAP (only 
in those with a previous Fontan)  2.4 <0.0001 
Longer ischemic time  1.6  0.002 
Older recipient age  1.5  0.02 
Interaction of donor age and ischemic 
time 1.4  0.0007 
    
Constant phase    
Previous classic Glenn operation  3.1  0.01 
CMV+ donor, CMV- recipient  2.8  0.001 
Higher systolic transpulmonary gradi-
ent 2.0  0.01 
Younger recipient age  1.8  0.0001 100    Current Cardiology Reviews, 2011, Vol. 7, No. 2  Mora and Huddleston 
CHD, further increasing the relative risk for heart transplan-
tation. Overall survival also varies depending on the underly-
ing CHD anomaly. For example, patients with TGA had the 
highest Kaplan-Meier survival, at 88%, compared to those 
with atrioventricular canal defects, which fared the worst, at 
62% survival, p=0.02.  
  In a study from Columbia University on heart transplan-
tation for complex congenital heart disease, there was a trend 
for various anatomic subgroups to have different odds ratio 
for overall mortality, although this was not statistically sig-
nificant due to small sample sizes and variable periods of 
follow-up [11]. Patients with tetralogy of Fallot had an odds 
ratio for mortality of 2.0, transposition of the great arteries 
had an odds ratio of 1.6, pulmonary atresia had an odds ratio 
of 1.4, while pulmonary stenosis had an odds ratio of 1.2. In 
that study, patients who underwent any pulmonary artery 
reconstruction had inferior Kaplan-Meier survival curves 
compared to patients who did not require pulmonary artery 
reconstruction, p=0.053. Regression analysis of survival re-
vealed that any pulmonary artery reconstruction carried an 
odds ratio of 3.3, while transplantation in a neonate carried 
an odds ratio of 5.2; male gender was protective with an 
odds ratio of 0.5, and a more recent year of transplantation 
was mildly protective with an odds ratio of 0.9. 
  A recent analysis by the Great Ormond Street Hospital 
for Children of 73 patients with CHD treated since 1988 re-
vealed similar survival for patients with univentricular and 
biventricular CHD anomalies [28]. One-year survival for 
univentricular physiology was 75% vs 78% for biventricular 
physiology, p=NS. At one-month post-transplant, a total of 8 
of 38 univentricular patients and 5 of 35 biventricular pa-
tients had died, p=NS. See Fig. 4. This result, however, may 
be due to the small sample size, as this has not been repro-

















  A number of post-transplant complications have been 
recognized following heart transplantation, applicable to all 
recipient subgroups. These have been extensively reviewed 
elsewhere [29], and are beyond the scope of this manuscript. 
Issues specific to patients with biventricular CHD are ad-
dressed below. 
Bleeding 
  The need for redo sternotomy in the setting of palliated 
or repaired biventricular CHD increases the incidence of 
postoperative bleeding. Since aprotinin is no longer avail-
able, other antifibrinolytic agents such as tranexamic acid or 
epsilon aminocaproic acid have been used, although their 
efficacy has not been demonstrated.  
Acute Rejection 
  Although neonates and young infants have higher pe-
rioperative mortality, they experience lesser rates of acute 
rejection and often can be managed with decreased levels of 
immunosuppression. This is due to a naïve and immature 
immune system, which also allows for ABO-incompatible 
heart transplantation. Patients with biventricular CHD often 
have elevated panel reactive antibodies, which increase the 
incidence of acute cellular rejection and antibody-mediated 
rejection. This is thought to be a major factor influencing the 
lower survival following heart transplantation in this group 
compared to patients with cardiomyopathy. 
Post-Transplant Lymphoproliferative Disease 
  This complication occurs in 5-10% of patients postopera-
tively. Specific studies in patients with biventricular CHD 
have not been performed. 
Cardiac Allograft Vasculopathy 
When compared to cardiomyopathy, CHD increases the in-
cidence of CAV within five years following heart transplan-
tation, with a relative risk of 1.36 based on the most recent 
ISHLT Registry analysis, p=0.08 [3]. This increased inci-
dence of chronic rejection likely stems from increased pre-
formed antibodies as well as the need for greater blood prod-
ucts during redo sternotomy procedures. The prior use of 
homograft tissue, when present, also increases the incidence 
of preformed antibodies and likely contributes to a greater 
incidence of acute and chronic rejection. 
CONCLUSIONS 
  Patients with biventricular CHD represent a heterogene-
ous group of patients with varied anatomic substrates, prior 
surgeries, age, and clinical status. With increasing experi-
ence, results for heart transplantation in this subgroup con-
tinue to improve, although are still inferior to transplantation 
for cardiomyopathy. It is hoped that further refinements in 
patient selection, techniques, and postoperative management 
will result in continued improvements in outcomes of heart 
transplantation for patients with biventricular congenital 
heart disease.  
ABBREVIATIONS 
CCTGA  =  Congenitally-corrected transposition of the 
great arteries Heart Transplantation in Biventricular Congenital Heart Disease  Current Cardiology Reviews, 2011, Vol. 7, No. 2    101 
CHD  =  Congenital heart disease 
CPB =  Cardiopulmonary  bypass 
ECMO  =  Extracorporeal membrane oxygenation 
HLHS  =  Hypoplastic left heart syndrome 
PAIVS  =  Pulmonary atresia with intact ventricular 
septum 
PRA =  Panel  reactive  antibody 
PTLD =  Post-transplant  lymphoproliferative  dis-
ease 
PVR  =  Pulmonary vascular resistance 
RVDCC  =  Right ventricle dependent coronary circu-
lation 
SVC  =  Superior vena cava 
TGA  =  Transposition of the great arteries 
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